1. Francis, GS, Gassler, JP, Sonnenblick, EH. Heart Failure. In Fuster C, Alexander RW, O’Rourke RA (eds). The Heart, 10th edn. International Edition, McGraw-Hill, New York, 2001; 653–685.
2. Jefferies, JL, Chang, AC. The neurohormonal axis and biochemical markers of heart failure. Cardiol Young 2005; 15: 333–344.
3. Valderheyden, M, Bartunek, J, Goethals, M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004; 6: 261–268.
4. Hall, C. Essential biochemistry and physiology of (NT-pro) brain natriuretic peptide. Eur J Heart Fail 2004; 6: 257–260.
5. Weber, M, Hamm, C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92: 843–849.
6. Ambrose, TM. A review of the clinical utility of NT-proBNP in the diagnosis, prognosis and therapy monitoring of patients with congestive heart failure. J Clin Ligand Assay 2003; 25: 160–166.
7. Cowie, MR, Struthers, AD, Wood, DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349–1353.
8. Mir, TS, Marohn, S, Laer, S, Eiselt, M, Grollmus, O, Weil, J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and children with congestive heart failure. Pediatrics 2002; 110: 76–81.
9. Mueller, T, Gegenhuber, A, Poelz, W, Haltmayer, M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005; 91: 606–612.
10. Murray, H, Cload, B, Collier, CP, Sivilotti, ML. Potential impact of N-terminal pro-BNP testing on the emergency department evaluation of acute dyspnea. CJEM 2006; 8: 251–258.
11. Moe, GM. B-type natriuretic peptide in heart failure. Curr Opin Cardiol 2006; 21: 208–214.
12. Koulouri, S, Acherman, RJ, Wong, PC, Chan, LS, Lewis, AB. Utilty of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric with respiratory distress. Pediatr Cardiol 2004; 25: 341–346.
13. Cohen, S, Springer, C, Avital, A. Amino-terminal pro-brain natriuretic peptide: Heart or lung disease in pediatric respiratory distress? Pediatrics 2005; 115: 1347–1350.
14. Dreyer, WJ, Fisher, DJ. Clinical Recognition and management of chronic congestive heart failure. In Garson A, Bricker JT, Fisher DJ and Neish SR (eds). The science and practice of pediatric cardiology, 2nd edn. Williams and Wilkins, Baltimore, 1998; 1582–1587.
15. James, N, Smith, M. Treatment of heart failure in children. Current Paediatrics 2005; 15: 539–548.
16. Koch, A, Singer, H. Normal values of B type natriuretic peptide in infants, children and adolescents. Heart 2003; 89: 875–878.
17. Mir, TS, Flato, M, Falkenberg, J, et al. Plasma consentrations of N-terminal brain natriuretic peptide in healthy children, adolescents and young adults: effect of age and gender. Pediatr Cardiol 2006; 27: 73–77.
18. Cowley, CG, Bradley, JD, Shaddy, RE. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004; 25: 336–340.
19. Koch, A, Zink, S, Singer, H. B-type natriuretic peptide in paediatric patents with congenital heart disease. Eur Heart J 2006; 27: 861–866.
20. Shann, F, MacGregor, D, Richens, J, Coakley, J. Cardiac failure in children with pneumonia in Papua New Guinea. Pediatr İnfect Dis J 1998; 17: 1141–1443.
21. İlten, F, Şenocak, F, Zorlu, P, Teziç, T. Cardiovascular changes in children with pneumonia. Turk J Pediatr 2003; 45: 306–310.
22. Wang, YL, Liu, W, Jiang, P. Myokardial protective effect of puerarin injection in children with severe pneumonia. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 25: 502–504.
23. Ross, RD, Bollinger, RO, Pinsky, WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 1992; 13: 72–75.
24. Laer, S, Mir, TS, Behn, F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 916–922.
25. An, JD, Zhang, YP, Zhou, JH. Levels of serum brain natriuretic peptide in children with congestive heart failure or with severe pneumonia. Zhongguo Dang Dai Er Ke Za Zhi 2006; 8: 201–204.
26. Meliones, JN, Cheifetz, IM. Pulmonary physiology and heart-lung interactions. In Garson A, Bricker JT, Fisher DJ and Neish SR (eds). The Science and Practice of Pediatric Cardiology, 2nd edn. Williams and Wilkins, Baltimore, 1998; 279–312.
27. Seedat, MA, Feldman, C, Skoularigis, J, Prommnitz, DA, Smith, C, Zwi, S. A study of acute community-acquired pneumonia, including details of cardiac changes. Q J Med 1993; 86: 669–675.
28. Bayes-Genis, A, Santalo-Bel, M, Zapico-Muniz, E, et al. N-terminal probrain natriuretic peptide in the emergency diagnosis and in-hospital monitoring of patients with dysnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6: 301–308.
29. Bettencourt, P. NT pro-BNP and BNP: biomakers for heart failure management. Eur J Heart Fail 2004; 6: 359–363.
30. Suda, K, Matsumura, M, Matsumoto, M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003; 45: 249–254.
31. Maeda, K, Tsutamoto, T, Wada, A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587–1593.
32. Pfister, R, Scholz, M, Wielckens, K, Erdmann, E, Schneider, CA. Use of NT pro-BNP in routine testing and comparison to BNP. Eur J Heart Fail 2004; 6: 289–293.
33. Seino, Y, Ogawa, A, Yamashita, T, et al. Application of NT pro-BNP and BNP measurements in cardiac care: a more discerning marker of the detection and evaluation of heart failure. Eur J Heart Fail 2004; 6: 295–300.
34. Wu, YR, Chen, SB, Huang, MR, Zhang, YQ, Sun, K, Chen, S. Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects. Zhonghua Er Ke Za Zhi 2005; 43: 161–164.
35. Maisel, A. B-type natriuretic peptide levels: a potential novel “white count” for congestive heart failure. J Card Fail 2001; 7: 183–193.
36. Mir, TS, Falkenberg, J, Friedrich, B, et al. Levels of brain natriuretic peptide in children with right ventricular overload due to congenital cardiac disease. Cardiol Young 2005; 15: 396–401.